| author name | recommending | commenting | favorite | papers | recom. | cited | |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 16 | 0 | 264 | [Update] | |
| 0 | 0 | 0 | 12 | 0 | 2 | [Update] | |
| 0 | 0 | 0 | 4 | 0 | 3 | [Update] | |
| 0 | 0 | 0 | 2 | 0 | 27 | [Update] | |
| 0 | 0 | 0 | 1 | 0 | 1 | [Update] |
Latest Paper:
Rebecka R Malterling,
Roland E Andersson,
Sture Falkmer,
Ursula Falkmer,
Eva Niléhn,
Johannes Järhult
Department of Surgery, Ryhov Hospital, Jönköping, Sweden.
Abstract Background. There is still no complete agreement about the proper treatment of differentiated thyroid cancer (DTC). Material and methods. All patients (n=130) with DTC in a defined population, treated with surgery between 1985 and 1999, were carefully followed up (median 13.1 years). Fifty three were operated with subtotal and 77 with total thyroidectomy. Twenty seven percent of the patients in the subtotal group and 56% of those in the total thyroidectomy group had postoperative radioiodine ablation. Thirty nine patients had papillary cancers incidentally detected during surgery for benign disorders (median size 7 (1-30) mm). Living patients answered the Swedish version of the SF-36 health survey. Results. Eleven of 106 patients considered tumour-free after primary surgery developed recurrences during follow-up. Fifteen patients (12%) died from DTC but only one within stage I-II (1.2%). No patient below 50 years of age at diagnosis died from DTC. Only three of 29 patients with isolated loco-regional spreading of their disease at the time of diagnosis have died from thyroid cancer. There was no statistically significant difference in the 10 year cancer-specific survival rate between those operated with subtotal or total thyroidectomy - irrespective of stage. Survival rate was significantly better for papillary than for follicular cancer. Mental and physical quality of life among patients treated for DTC were similar to the healthy Swedish population. Conclusions. Patients with DTC stage I-II (according to TNM) or low-risk (according to AMES) have an excellent prognosis. Treatment as well as follow-up should not be exaggerated.
Marie Rubér,
Manne Andersson,
B Fredrik Petersson,
Gunnar Olaison,
Roland E Andersson,
Christina Ekerfelt
Faculty of Health Sciences, Department of Clinical and Experimental Medicine, Surgery, Linköping University, Linköping, Sweden; Department of Surgery, County Hospital Ryhov, Jönköping, Sweden.
BACKGROUND: Increasing circumstantial evidence suggests that not all patients with appendicitis will progress to perforation and that appendicitis that resolves may be a common event. Based on this theory and on indications of aberrant regulation of inflammation in gangrenous appendicitis, we hypothesized that phlegmonous and gangrenous appendicitis are different entities with divergent immunoregulation. METHODS: Blood samples were collected from patients with gangrenous appendicitis (n = 16), phlegmonous appendicitis (n = 21), and nonspecific abdominal pain (n = 42). Using multiplex bead arrays, we analyzed a range of inflammatory markers, such as interleukin (IL)-1ra, IL-1rbeta, IL-2, IL-6, IL-10, IL-12p70, IL-15, and IL-17; interferon-gamma; tumor necrosis factor; CXCL8; CCL2; CCL3; and matrix metalloproteinase (MMP)-1 MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, and MMP-13 in blood. RESULTS: Compared with patients with phlegmonous appendicitis and nonspecific abdominal pain, the patients with gangrenous appendicitis had increased levels of the proinflammatory markers IL-6, CCL2, IL-17, MMP-8, and MMP-9 (P </=.04 each) accompanied by increased levels of the anti-inflammatory cytokines IL-1ra and IL-10 (P </=.02). Patients with phlegmonous appendicitis had increased levels of IL-10 only. CONCLUSION: The finding of a pattern of inflammatory markers compatible with the highly inflammatory Th17 subset in sera from patients with gangrenous appendicitis, but not in phlegmonous appendicitis, supports the hypothesis that gangrenous and phlegmonous appendicitis are different entities with divergent immune regulation. Additional studies of the differential immunopathogenesis of phlegmonous and gangrenous appendicitis are warranted, as this may have important implications in the diagnosis and management of patients with suspicion of appendicitis.
Department of Surgery, County Hospital Ryhov, Jönköping, Sweden.
Keywords:
Department of Epidemiology Research, Division of Epidemiology, Statens Serum Institut, DK-2300 Copenhagen S, Denmark. mfr@ssi.dk
OBJECTIVE: To determine whether the repeatedly observed low risk of ulcerative colitis after appendicectomy is related to the appendicectomy itself or the underlying morbidity, notably appendicitis or mesenteric lymphadenitis. DESIGN: Nationwide cohort studies. SETTING: Sweden and Denmark. PARTICIPANTS: 709 353 Swedish (1964-2004) and Danish (1977-2004) patients who had undergone appendicectomy were followed up for subsequent ulcerative colitis. The impact of appendicectomy on risk was also studied in 224 483 people whose parents or siblings had inflammatory bowel disease. MAIN OUTCOME MEASURES: Standardised incidence ratios and rate ratios as measures of relative risk. RESULTS: During 11.1 million years of follow-up in the appendicectomy cohort, 1192 patients developed ulcerative colitis (10.8 per 100 000 person years). Appendicectomy without underlying inflammation was not associated with reduced risk (standardised incidence ratio 1.04, 95% confidence interval 0.95 to 1.15). Before the age of 20, however, appendicectomy for appendicitis (0.45, 0.39 to 0.53) or mesenteric lymphadenitis (0.65, 0.46 to 0.90) was associated with significant risk reduction. A similar pattern was seen in those with affected relatives, whose overall risk of ulcerative colitis was clearly higher than the background risk (1404 observed v 446 expected; standardised incidence ratio 3.15, 2.99 to 3.32). In this cohort, appendicectomy without underlying appendicitis did not modify risk (rate ratio 1.04, 0.66 to 1.55, v no appendicectomy), while risk after appendicectomy for appendicitis was halved (0.49, 0.31 to 0.74). CONCLUSIONS: In individuals with or without a familial predisposition to inflammatory bowel disease, appendicitis and mesenteric lymphadenitis during childhood or adolescence are linked to a significantly reduced risk of ulcerative colitis in adulthood. Appendicectomy itself does not protect against ulcerative colitis.
Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada.
BACKGROUND: Studies exploring the association between appendectomy and Crohn's disease (CD) have reported conflicting findings. We conducted a systematic review of the literature and a meta-analysis to assess the risk of CD following an appendectomy and determine the effect of time between appendectomy and CD diagnosis. METHODS: MEDLINE was used to identify observational studies evaluating the association between appendectomy and CD. Authors were contacted when data were insufficient. Relative risks (RR) with 95% confidence intervals (CI) were calculated using a random effects model. Studies that analyzed their data by the interval between the appendectomy and the diagnosis of CD were assessed separately. The Woolf chi(2) statistic was used to test for homogeneity. Egger's test was used to evaluate publication bias. RESULTS: The summary RR estimate for CD following an appendectomy was significantly elevated (RR 1.61, 95% CI 1.28-2.02), though heterogeneity was observed (P < 0.0001). The risk was elevated within the first year following the operation (RR 6.69, 95% CI 5.42-8.25). The risk of CD was also significantly increased 1-4 yr following an appendectomy (RR 1.99, 95% CI 1.66- 2.38); however, after 5 yr or more, the risk fell to baseline levels (RR 1.08, 95% CI 0.99-1.18). Publication bias was not detected (P= 0.2). CONCLUSION: The meta-analysis demonstrated a significant risk of CD following an appendectomy, though heterogeneity was observed between the studies. The elevated risk early after an appendectomy, which diminishes thereafter, likely reflects diagnostic problems in patients with incipient CD.
Department of Surgery, Ryhov County Hospital, Jönköping SE55185, Sweden.
Keywords:
Department of Surgery, County Hospital Ryhov, Jönköping, Sweden and Department of Surgery, Linköping University Hospital, Linköping, Sweden, rolandersson@gmail.com.
Keywords:
Massachusetts General Hospital Crohn's and Colitis Center & Harvard University, United States.
BACKGROUND: The relationship between appendectomy and Crohn's disease (CD) is controversial. We conducted a Swedish-Danish cohort study to assess the risk of developing CD after an appendectomy. METHODS: 709,353 appendectomy patients in Sweden (since 1964) and Denmark (since 1977) were followed for first hospitalizations for CD through 2004. Standardized incidence ratios (SIRs) served as relative risks. RESULTS: Overall, 1655 CD cases were observed during 11.1 million person-years of follow-up. While appendectomy before age 10 was not associated with CD risk (SIR = 1.00; 95% confidence interval (CI): 0.80 - 1.25), the overall SIR of developing CD was 1.52 (95% CI: 1.45 - 1.59), being highest in the first 6 months (SIR = 8.69; 95% CI: 7.68 - 9.84). SIRs diminished rapidly thereafter, with CD risk reaching background levels after 5-10 years for CD overall, as well as for Crohn's ileitis, ileocolonic CD, Crohn's colitis and other/unspecified CD. Long-term increased CD risk up to 20 years after the appendectomy was seen only in appendectomy patients without appendicitis or mesenteric lymphadenitis. CONCLUSION: The transient increased risk of Crohn's disease following an appendectomy is likely explained by a diagnostic bias.
Department of Food Sciences and 3Department of Chemistry, Swedish University of Agricultural Sciences, S-750 07 Uppsala, Sweden.
Sesamin, the major sesame oil lignan, is recognized for its health-promoting effects, including the lowering of cholesterol and elevation of gamma-tocopherol in rats and humans. However, little is known about the absorption and metabolism of sesamin in humans. In this study, 6 healthy volunteers took a single dose of sesame oil (508 mumol sesamin) and their urine was collected for four 12-h periods. The urine samples were treated with beta-glucuronidase/sulphatase and extracted with chloroform. The major urinary sesamin metabolite in the chloroform extract was collected using HPLC diode array detector and characterized as (1R,2S,5R,6S)-6-(3,4-dihydroxyphenyl)-2-(3,4-methylenedioxyphenyl)-3,7-dioxabicyclo-[3,3,0]octane using NMR and mass spectroscopy. A quantitative (1)H-NMR technique, based on the methylenedioxyphenyl protons signal (delta 5.91), was used for the quantification of the metabolite in the chloroform extracts of urine. The excretion of the sesamin catechol metabolite ranged from 22.2 to 38.6%(mean +/- SD, 29.3 +/- 5.6) of the ingested dose and happened mainly in the 1st 12 h after ingestion.
Mesh-terms: Acquired Immunodeficiency Syndrome :: prevention & control; Acquired Immunodeficiency Syndrome :: transmission; Africa; Communicable Disease Control; Condoms; Disease Outbreaks :: prevention & control; HIV Infections :: prevention & control; HIV Infections :: transmission; Humans; Life Style; Safe Sex; Sexual Behavior;
